Showing results (1-10 of 90) with videos related to
Sort By:
Pageof 9
Journal of Dentistry|January 1, 1989
A posterior composite teaching programme for the postgraduateP A WanderClinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 6, 2024
Cracking the Genomic Code of CDK4/6 Inhibitor ResistanceSeth A Wander, Aditya BardiaClinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 23, 2010
p27: a barometer of signaling deregulation and potential predictor of response to targeted therapiesSeth A Wander, Dekuang Zhao, Joyce M SlingerlandJournal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2017
Blocking the Cycle: Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic, Hormone Receptor-Positive Breast CancerSeth A Wander, Erica L Mayer, Harold J BursteinCell Cycle (Georgetown, Tex.)|October 16, 2009
p27 as Jekyll and Hyde: regulation of cell cycle and cell motilityMichelle D Larrea, Seth A Wander, Joyce M SlingerlandThe Journal of Clinical Investigation|April 15, 2011
Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategySeth A Wander, Bryan T Hennessy, Joyce M SlingerlandTherapeutic Advances in Hematology|June 3, 2014
The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyondSeth A Wander, Mark J Levis, Amir T FathiClinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2026
Beyond amplification: precision approaches to targeting HER2Maxwell R Lloyd, Mark D Pegram, Seth A WanderSeminars in Hematology|June 27, 2015
Biochemical, Epigenetic, and Metabolic Approaches to Target IDH Mutations in Acute Myeloid LeukemiaAmir T Fathi, Seth A Wander, Rawan Faramand, et al.Current Oncology Reports|February 27, 2019
CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future DirectionsLaura M Spring, Seth A Wander, Mark Zangardi, et al.Pageof 9